Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
Sponsor: Hikma Pharmaceuticals LLC
Listed as NCT03625388, this PHASE2 trial focuses on Chronic Myelogenous Leukemia and remains completed. Sponsored by Hikma Pharmaceuticals LLC, it has been updated 11 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Oct 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hikma Pharmaceuticals LLC
For direct contact, visit the study record on ClinicalTrials.gov .